BOULDER, Colo., Oct. 20, 2020 (GLOBE NEWSWIRE) -- AeroGrow International, the manufacturer and distributor of AeroGardens – the world’s leading family of In-Home Garden Systems™ – announced today a new partnership with World Champion gymnast, wellness advocate, and avid gardener Aly Raisman. The partnership will amplify the duo’s shared passion for gardening and the role it plays in Raisman’s self-care routine.“Gardening is a passion of mine and a huge part of my wellness journey, so I am excited to be partnering with AeroGarden to encourage others to discover the pleasure of gardening and the benefits of growing at home,” said Raisman. “I’ve been using AeroGardens for some time now, and I love that I can use their gardens to grow fresh herbs, veggies and plants indoor, all year round. My mom and I even have contests using different models to see whose veggies and herbs grow faster!”Raisman will be documenting her growing journey this fall to demonstrate how the AeroGarden process simplifies cultivating homegrown herbs, veggies, and flowers, no matter the season.“We couldn’t be more excited to be partnering with Aly,” AeroGarden Marketing Director Paul Rabaut stated. “She’s a friend of the mission in every way, and from the very first conversations we had with her, it was easy to see how passionate she is about the benefits of gardening. Working with Aly is the absolute perfect match.”In addition to showcasing her growing journey, Raisman will work closely with the AeroGarden team by supporting key marketing efforts, hosting virtual meet and greets for sweepstakes winners, and appearing in video content in which she will share tips on gardening and growing, while promoting the many benefits of AeroGarden.For further information please contact Susan Mallory (551.404.3963 / Susan@MastersMallory.com) or Sydney Masters (212.987.6804 / Sydney@MastersMallory.com).About AeroGrow International, Inc. Headquartered in Boulder, Colorado, AeroGrow International, Inc. is the leader in the rapidly growing indoor gardening category. AeroGardens allow anyone to grow farmer's market fresh herbs, salad greens, tomatoes, chili peppers, flowers and more, indoors, year-round, so simply and easily that no green thumb is required. With an AeroGarden, you can grow anything! For more information, visit www.AeroGarden.com.
TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX / TSX: CDV) (“Cardinal” or “the Company”) is providing an update to shareholders in reference to the ongoing takeover offers for the Company by Shandong Gold Mining (HongKong) Co., Ltd. (“Shandong Gold”) and Nord Gold S.E. (“Nordgold”). Status of Takeover BidsCardinal notes the recent extension by Nordgold on 15 October 2020 of its unconditional on-market A$0.90 per share offer (“Nordgold Offer”) to the close of trading on the ASX on 3 November 2020 (unless further extended or withdrawn).Cardinal also notes the Second Supplementary Bidder’s Statement lodged by Shandong Gold on 19 October 2020 in relation to its recommended and unconditional off-market A$1.00 per share takeover offer (“Shandong Gold Offer”). Pursuant to the Second Supplementary Bidder’s Statement, Shandong Gold has now declared the A$1.00 cash per share offered to be Shandong Gold’s best and final offer price in the absence of a higher competing offer. The practical effect of this statement is that unless there is a higher competing offer to the Shandong Gold Offer (whether from Nordgold or a third party), Shandong Gold cannot increase its offer price.The Nordgold Offer continues to be materially inferior to the A$1.00 cash per share offered by the Shandong Gold Offer. Cardinal notes that while Nordgold has the right to continue to extend the Nordgold Offer, the most recent extension announcement is the 4th successive extension by Nordgold as the “Underbidder” and the 2nd extension following the Shandong Gold Offer becoming unconditional.Cardinal considers that the lack of any price increase or any other updated guidance from Nordgold as to its current intentions with respect to Cardinal will result in unwarranted delays to the progression of the Namdini Gold Project and will continue to frustrate the decision making process of Cardinal’s shareholders.Over 7 months have elapsed since the initial unsolicited, indicative, conditional and non-binding proposal from Nordgold was originally received in March 2020 when Cardinal’s share price was trading at a 3 year low during the early stages of the COVID 19 pandemic.Cardinal’s permitted Namdini Gold Project is ready for development. Cardinal’s 2019 feasibility study has shown the superior economics of the Namdini Gold Project using a USD$1,350 gold price (without taking into account the far stronger gold price at present).1 Work on the ground and detailed engineering works are poised to commence. The Government of Ghana continues to be fully supportive of moving the Namdini Gold Project towards production and, being a permitted project, progress is now vital.Cardinal makes the following key observations in respect of the competing takeover offers for Cardinal shareholders to consider at present: * As Shandong Gold has now declared the A$1.00 cash per share offered by the Shandong Gold Offer to be Shandong Gold’s best and final offer price, unless there is a higher competing offer for Cardinal (whether from Nordgold or a third party), Shandong Gold cannot increase its offer price; * Any Cardinal shareholder who accepts the Shandong Gold “off-market” takeover offer will benefit from any potential increase in offer price which may be made by Shandong Gold, should Shandong Gold increase its offer price prior to the close of its offer – Cardinal does not know if Shandong Gold will increase its offer price, but Shandong Gold has reserved its right to do so in its agreement with Cardinal; * Any Cardinal shareholder who accepts Nordgold’s takeover offer will not benefit from any potential future increase in the offer price offered by Nordgold (as such shares will have been sold “on-market”) – this means that a decision to accept the Nordgold Offer locks in the final return that a Cardinal Shareholder will receive for their shares; * Following the most recent extension by Nordgold as the “Underbidder”, the Nordgold Offer is currently scheduled to close at the close of trading on ASX on 3 November 2020 (unless extended or withdrawn). If Nordgold wishes to extend the offer period of the Nordgold Offer, then (unless certain special cases apply) Nordgold must do so before the last five trading days of its offer period (currently, the end of trading on 27 October 2020, unless extended). * The Shandong Gold Offer, unanimously recommended by the Cardinal Board, is unconditional and is currently scheduled to close at 7pm (Sydney time / AEDT) on 23 October 2020 (unless extended or withdrawn). If Shandong Gold wishes to extend the Shandong Gold Offer, then Shandong Gold may do so at any time before the Shandong Gold Offer closes; and * Under the Bid Implementation Agreement (as varied) with Shandong Gold and Shandong Gold Mining Co., Ltd., Shandong Gold has “matching rights” which provide Shandong Gold with a brief period of time to provide a matching or superior offer to any competing transaction made for Cardinal by any other party. In the event the “matching right” is triggered, Cardinal will keep shareholders advised on the outcome of that event. Update on Shandong Gold OfferThe highest offer presently made to Cardinal shareholders, and unanimously supported by the Cardinal Board, is A$1.00 cash per share, offered by Shandong Gold. On 19 October 2020, Shandong Gold declared its offer to be best and final in the absence of a higher competing offer. Shandong Gold has acquired a Relevant Interest of 11.86% in Cardinal based on its most recent regulatory filing at the time of this announcement. The Shandong Gold Offer is currently scheduled to close at 7pm (Sydney time) on 23 October 2020 (unless extended or withdrawn).Update on Nordgold OfferNordgold is offering Cardinal shareholders a price of A$0.90 cash per share pursuant to its unconditional on-market takeover offer. Nordgold has acquired a Relevant Interest of 28.39% in Cardinal based on its most recent regulatory filing at the time of this announcement. Following the most recent extension announcement by Nordgold on 15 October 2020, the Nordgold Offer is currently scheduled to close at the close of trading on ASX on 3 November 2020 (unless extended or withdrawn). If Nordgold wishes to extend the offer period of the Nordgold Offer, then (unless certain special cases apply) Nordgold must do so before the last five trading days of its offer period (currently, the end of trading on 27 October 2020, unless extended).The Cardinal Board continues to unanimously recommend that Cardinal Shareholders ACCEPT the Shandong Gold Offer (in the absence of a Superior Proposal) and TAKE NO ACTION in respect of the Nordgold Offer.Advisors Cardinal’s joint financial advisers are Maxit Capital LP, BMO Capital Markets, Euroz Hartleys Limited and Canaccord Genuity Corp. Cardinal’s legal advisers are HopgoodGanim Lawyers (Australia) and Bennett Jones LLP (Canada).ABOUT CARDINALCardinal Resources Limited (ASX/TSX: CDV) is a West African gold‐focused exploration and development Company that holds interests in tenements within Ghana, West Africa.The Company is focused on the development of the Namdini Gold Project and released its Feasibility Study on 28 October 2019.Cardinal confirms that it is not aware of any new information or data that materially affects the information included in its announcement of the Ore Reserve of April 3, 2019. All material assumptions and technical parameters underpinning this estimate continue to apply and have not materially changed.*The Namdini Project has a published gold Ore Reserve of 5.1 Moz (138.6 Mt @ 1.13 g/t Au; 0.5 g/t cut-off), inclusive of 0.4 Moz Proved (7.4 Mt @ 1.31 g/t Au; 0.5 g/t cut-off) and 4.7 Moz Probable (131.2 Mt @ 1.12 g/t Au; 0.5 g/t cut-off). Authorised for release by the Board of Cardinal Resources Limited.For further information contact: Sarah Shipway Company Secretary Cardinal Resources Limited P: +61 8 6558 0573 Alec Rowlands IR / Corp Dev Cardinal Resources Limited P: +1 647 256 1922 Cannings Purple (Investor Relations, Australia) Warrick Hazeldine E: firstname.lastname@example.org Competent / Qualified Person StatementThe scientific and technical information in this announcement that relates to Exploration Results, Mineral Resources and Ore Reserves at the Namdini Gold Project has been reviewed and approved by Mr. Richard Bray, a Registered Professional Geologist with the Australian Institute of Geoscientists and Mr. Ekow Taylor, a Chartered Professional Geologist with the Australasian Institute of Mining and Metallurgy. Mr. Bray and Mr. Taylor have more than five years’ experience relevant to the styles of mineralisation and type of deposits under consideration and to the activity which is being undertaken to qualify as a Competent Person, as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” and as a Qualified Person for the purposes of NI43‐101. Mr. Bray and Mr. Taylor are full‐time employees of Cardinal and hold equity securities in the Company.For further information on the Namdini project please see the Feasibility Study (FS) for the Namdini Gold Project, titled "Namdini Gold Project Feasibility Study 43‐101 Report" by David Gordon, FAusIMM, Daryl Evans, FAusIMM, Nicolas Johnson, MAIG MPRm and Glenn Turnbull, FIMMM, MAusIMM, which was released on October 28, 2019. The technical report on the Feasibility Study, pursuant to NI 43‐101 of the Canadian Securities Administrators, was issued on SEDAR at www.sedar.com on November 28, 2019.Disclaimer Cardinal confirms that it is not aware of any new information or data that materially affects the information included in its announcement of the Ore Reserve of April 3, 2019. All material assumptions and technical parameters underpinning this estimate continue to apply and have not materially changed.This ASX / TSX press release has been prepared by Cardinal Resources Limited (ABN: 56 147 325 620) (“Cardinal” or “the Company”). Neither the ASX or the TSX, nor their regulation service providers accept responsibility for the adequacy or accuracy of this press release.This press release contains summary information about Cardinal, its subsidiaries and their activities, which is current as at the date of this press release. The information in this press release is of a general nature and does not purport to be complete nor does it contain all the information, which a prospective investor may require in evaluating a possible investment in Cardinal.By its very nature exploration for minerals is a high‐risk business and is not suitable for certain investors. Cardinal’s securities are speculative. Potential investors should consult their stockbroker or financial advisor. There are a number of risks, both specific to Cardinal and of a general nature which may affect the future operating and financial performance of Cardinal and the value of an investment in Cardinal including but not limited to economic conditions, stock market fluctuations, gold price movements, regional infrastructure constraints, timing of approvals from relevant authorities, regulatory risks, operational risks and reliance on key personnel and foreign currency fluctuations.Except for statutory liability which cannot be excluded and subject to applicable law, each of Cardinal’s officers, employees and advisors expressly disclaim any responsibility for the accuracy or completeness of the material contained in this press release and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this Announcement or any error or omission here from. Except as required by applicable law, the Company is under no obligation to update any person regarding any inaccuracy, omission or change in information in this press release or any other information made available to a person nor any obligation to furnish the person with any further information. Recipients of this press release should make their own independent assessment and determination as to the Company’s prospects, its business, assets and liabilities as well as the matters covered in this press release.Forward‐looking statementsCertain statements contained in this press release, including information as to the future financial or operating performance of Cardinal and its projects may also include statements which are ‘forward‐looking statements’ that may include, amongst other things, statements regarding targets, anticipated timing of the feasibility study (FS) on the Namdini project, estimates and assumptions in respect of mineral resources and anticipated grades and recovery rates, production and prices, recovery costs and results, capital expenditures and are or may be based on assumptions and estimates related to future technical, economic, market, political, social and other conditions. These ‘forward – looking statements’ are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Cardinal, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies and involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward‐looking statements.Cardinal disclaims any intent or obligation to update publicly or release any revisions to any forward‐looking statements, whether as a result of new information, future events, circumstances or results or otherwise after today’s date or to reflect the occurrence of unanticipated events, other than required by the Corporations Act and ASX and TSX Listing Rules. The words ‘believe’, ‘expect’, ‘anticipate’, ‘indicate’, ‘contemplate’, ‘target’, ‘plan’, ‘intends’, ‘continue’, ‘budget’, ‘estimate’, ‘may’, ‘will’, ‘schedule’ and similar expressions identify forward‐looking statements.All forward‐looking statements made in this press release are qualified by the foregoing cautionary statements. Investors are cautioned that forward‐looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward‐looking statements due to the inherent uncertainty therein.____________________ 1 Refer to ASX/TSX Announcement “Mineral Resource and Ore Reserve Statement” released on the ASX/TSX on 15 October 2019 and ASX Announcement “Feasibility Study Confirms Namdini as Tier One Gold Project” released on ASX on 28 October 2019.
Most brokerages require two-factor authentication that adds another layer of security. However, popular fintech Robinhood does not — though the company is encouraging its customers to opt-in following a security incident.
Nine months after he was banned and fired in the wake of the Astros sign-stealing scandal, former GM Jeff Luhnow is speaking out.
The Global Waste Heat Recovery Market will grow by USD 11.31 bn during 2020-2024
Company announcement no. 40 - 20 20 October 2020 Transactions in connection with share buyback programOn May 25, 2020 NTG Nordic Transport Group (“NTG”) announced a share buyback program, as described in Company announcement 09 - 20. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules.The purpose of the program is to meet obligations relating to acquisition of minority shareholders’ shares in NTG subsidiaries under the “Ring-the-Bell” concept and to cover obligations arising under future share-based incentive programs and potentially for other purposes such as payment in relation to potential M&A transactions.Under the program NTG will purchase up to 200,000 of its own shares (nominally DKK 4,000,000), corresponding to 0.89% of the current share capital of NTG, for an aggregate maximum amount of DKK 20,000,000. The share buyback program will run from 26 May 2020 to 30 December 2020 at the latest, both days inclusive.The following transactions have been made under the program: Number of sharesAverage purchase priceTransaction value (DKK) Accumulated, latest announcement140,949 16,245,381 13 October 20202,818161.21454,279 14 October 20202,390171.62410,174 15 October 20203,792172.48654,027 16 October 20201,894179.82340,587 19 October 20204,106188.53774,108 Accumulated under the program155,949 18,878,554 With the transactions stated above, NTG owns a total of 173,734 treasury shares, corresponding to 0.77% of the company’s share capital.Details of each transaction are included as appendix.Additional information For additional information, please contact:Investor relations Christian D. Jakobsen, Group CFO +45 76 32 09 89 email@example.com Press Mathias Jensen-Vinstrup, Group Director +45 76 32 09 90 firstname.lastname@example.orgAttachments * Company announcement no 40_2020 * Appendix Company announcement no 40_2020
The "Vessel Sealing Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
Smartway2 workplace survey shows that employees are not interested in working from home full time post COVID-19, but prefer a hybrid work environment.
Oslo, 20 October 2020 You are cordially invited to participate in the presentation of Adevinta ASA’s Q3 2020 report on Tuesday 27 October 2020.Quarterly Earnings Release Time: 27 October 2020 at 07:00 CET Report for the third quarter 2020, presentation materials, and spreadsheet with key figures and analytical information will be made available on the investor relations pages at https://www.adevinta.com/irPresentation of the Quarterly Results Time: 27 October 2020 at 08:30 CET The company will conduct the presentation as a live audio webcast and conference call, including a Q&A session. CEO Rolv Erik Ryssdal and CFO Uvashni Raman will present. The whole management team of Adevinta will participate in the Q&A session.The webcast will be available on www.adevinta.com/ir and on this link: https://bit.ly/37kkL3P. Participants are also invited to ask questions using the dial-in numbers below.Dial-in details: Norway: +47 21 56 33 18 UK: +44 20 3003 2666 USA: +1 212 999 6659Password: adevintaA recording of the presentation will be available on our website shortly after the live webcast has ended.Contact information:Adevinta Investor Relations Marie de Scorbiac Head of Investor Relations +33 6 14 65 77 40 email@example.comAdevinta Media Relations Mélodie Laroche Corporate Communications +33 6 84 30 52 76 firstname.lastname@example.org***About Adevinta ASA Adevinta is a global online classifieds specialist, operating digital marketplaces in 15 countries. The company provides technology-based services to connect buyers with sellers and to facilitate transactions, from job offers to real estate, cars, consumer goods and more. Adevinta’s portfolio spans 35 digital products and websites, attracting 1.5 billion average monthly visits. Leading brands include top-ranked leboncoin in France, InfoJobs and Milanuncios in Spain, and 50% of fast-growing OLX Brazil. Adevinta spun off from Schibsted ASA and publicly listed in Oslo, Norway in 2019. Adevinta is majority owned by Schibsted ASA and employs 4,700 people committed to supporting users and customers daily. Find out more at Adevinta.com.***This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
AXA (AXA - FR0000120628), the leading insurance company, adopts Wiztrust, Wiztopic's news certification platform in the blockchain. Axa joins the community of listed companies and insurers that already rely on Wiztrust to guarantee the authenticity of their information and thus avoid fake news, protect their shareholders and preserve the reputation of their executives.
Mike Perry says he never abused his ex-wife after 911 audio leaked.
With the business potentially at an important milestone, we thought we'd take a closer look at Mandalay Resources...
Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today the publication of study results in the peer-reviewed journal Nature Communications. The study demonstrates the power of the company’s platform to detect pancreatic cancer in its early stages, addressing the unmet need of more than 60,000 patients diagnosed with the disease each year in the United States alone. The research shows that utilizing Bluestar’s epigenomic technology to analyze a simple blood draw effectively identifies the presence of pancreatic cancer in patients’ DNA circulating in their blood, enabling non-invasive, precise detection of the disease, which could lead to more timely treatment and improved patient survival.
Montreal-based YPC Technologies today announced that it has raised a $1.8 million seed round. Led by Hike Ventures and Real Ventures, the funding includes participation from Toyota AI Ventures and Uphill Capital, among others, designed to help the company pilot its kitchen robotics technology. Toyota’s funding came as part of the company’s “Call of Innovation,” which finds it investing in early state AI, robotics and other cutting edge technologies.
Andrew Siciliano says he's "ready to put Sunday behind me."
Google Photos' Portrait Light effects are now rolling out to older Pixel phones, not just the 5 and 4a 5G.
Innovative Pop-Up Gallery Offers Visitors New Ways to Interact With Porsche Brand Porsche NOW Markham Pfaff Automotive Partners has opened the doors to Ontario’s first Porsche NOW pop-up store at CF Markville, offering Porsche fans, prospects, and customers a unique experience with the brand. Porsche NOW Markham Pfaff Automotive Partners has opened the doors to Ontario’s first Porsche NOW pop-up store at CF Markville, offering Porsche fans, prospects, and customers a unique experience with the brand.TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- The doors to Ontario’s first Porsche NOW pop-up store opened today at CF Markville, offering Porsche fans, prospects, and customers a unique experience with the brand. Located on the ground floor of CF Markville, Porsche NOW is an expression of a new Porsche global design concept that provides an intimate and interactive Porsche sales environment, where visitors can interact with the Porsche brand, vehicles, and product experts in a unique, low-pressure environment.Operated by Pfaff Automotive Partners, one of Canada’s leading luxury vehicle retailers and one of the largest Porsche retailers in North America, the pop-up features two Porsche vehicles including the all-new, all-electric Taycan, a design centre offering visitors the ability to custom-configure their own Porsche, and sales of Porsche Driver’s Selection merchandise and accessories.Porsche NOW previews the opening of a full-service dealership on the grounds of CF Markville early in 2021. Porsche Centre Markham will be one of the first in the world to feature Porsche’s new global retail architecture, uniquely integrated within the site of the Markham shopping centre.About Pfaff Automotive Partners Pfaff Automotive Partners, a leading Canadian automotive retailer, was founded in 1964. Its brand offering includes Volkswagen, Chrysler, Dodge, RAM, Jeep, Mazda, Audi, BMW, MINI, Porsche, McLaren, Singer Vehicle Design, Pagani, BAC Mono, Harley-Davidson, Mercedes-Benz, Subaru, and Automobili Pininfarina automobiles and motorcycles. It has a 50-plus-year racing history across many forms of motorsport. The company also operates Pfaff Tuning, Pfaff Leasing, and Pfaff Autoworks. For more information, please visit www.pfaffauto.com.CONTACT Laurance Yap // email@example.com // 416.948.0672 Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/b0c240c7-1481-456a-b6b8-3a39bb8971echttps://www.globenewswire.com/NewsRoom/AttachmentNg/3cb9a141-8ca0-4a1c-997d-9da5ac636e94
The "New Energy Vehicles Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 To 2028" report has been added to ResearchAndMarkets.com's offering.
Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditionsWINTER PARK, Fla., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that they have entered into a definitive merger agreement to combine their businesses in an all-stock transaction. Cytocom shareholders will have a majority position in the newly combined entity, which the parties anticipate will continue to be listed on the Nasdaq, and the initial Board of Directors for the combined company will consist of four members selected by Cytocom and three members selected by Cleveland BioLabs. The Boards of Directors of both companies have approved the combination.For Immune Therapeutics, Inc. (Ticker: IMUN) and it’s shareholders who hold a considerable stake in Cytocom this means that the value for all of the years of support and collaboration with Cytocom can be realized. The Cytocom platform technologies and product pipeline, in combination with Cleveland BioLabs, have the potential to drive significant future growth in Immune’s shareholder value.Each party to the proposed merger believes that the combined company will create near-term commercial opportunities in numerous areas of significant unmet medical needs including acute radiation injury, oncology, infectious disease, inflammation and autoimmune-mediated conditions, with multiple commercial, regulatory and clinical milestones expected over the next 12 to 18 months. Operating as “Cytocom, Inc.” and under the leadership of Cytocom’s experienced management team, the combined company will be positioned for consistent growth.OverviewMichael K. Handley, President and Chief Executive Officer of Cytocom, stated, “Our merger with Cleveland BioLabs and its subsequent immune-focused platform will be a transformative growth opportunity for Cytocom and Cleveland BioLabs shareholders. We believe that the combination of these highly complementary late-stage pipelines will strengthen our position and advance our efforts to unlock the potential of immune-modulating agents in the treatment of serious medical conditions. Further, this merger will enhance our ability to become a recognized leader in immune-modulating treatments and builds on the momentum created by our recent acquisition of ImQuest Life Sciences. We plan to utilize the combined platform to further drive value with additional clinical and commercial products and continue to seek strategic partnerships and acquisitions.”Dr. Andrei Gudkov, Chief Scientific Officer of Cleveland BioLabs, said: “This is an exciting day for Cleveland BioLabs and a great opportunity for our stockholders. The merger with Cytocom will allow us to add the strength of our science and bright perspectives associated with Entolimod development in cancer treatment and radiation defense arenas with a string of immunomodulators developed by Cytocom to form a powerful blend of conceptually and scientifically aligned products. We believe that the merger with Cytocom is the ideal way to unlock the value of our technology platform and our lead drug candidate, Entolimod, and I look forward to seeing this exciting new therapy advance through the clinic.”ConditionsThe proposed transaction is subject to customary closing conditions, including approval by the stockholders of Cleveland Biolabs, the shares of the combined company being approved for listing on Nasdaq and a registration statement under the Securities Act becoming effective. Cytocom and Cleveland Biolabs expect the transaction to close during the first quarter of 2021.Conference CallCytocom will host a conference call and live audio webcast at 8:00 a.m. EDT on October 28th to discuss the merger and provide a strategic vision for the combined company. To access the conference call supported with slides, please dial 646-558-8656 with the meeting ID: 841 7826 2704 and passcode: 281020. The conference call can also be accessed at https://cleartrustonline.com/cytocom. Approximately two hours following the live event, a webcast replay of the conference call will be available on Cytocom’s website https://www.cytocom.com/investors/ for approximately 30 days. About CytocomCytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Specifically, Cytocom has four programs in late-stage clinical development in Crohn’s disease, Fibromyalgia, Multiple Sclerosis and Pancreatic Cancer. Cytocom believes that its technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels not achieved by other published immunotherapy approaches. Cytocom’s immunomodulatory technology restores the balance between the cellular (Th1) and the humoral (Th2) immune systems. Immune balance is regulated through T-helper cells that produce cytokines. The Th1 lymphocytes help fight pathogens within cells like cancer and viruses through interferon-gamma and macrophages. The Th2 lymphocytes target external pathogens like cytotoxic parasites, allergens, toxins through the activation of B-cells and antibody production to effect to dendritic cells, which are natural activators of killer T cells, also known as cytotoxic T cells, or CD8+ T cells. Furthermore, the Cytocom technology antagonizes the Toll-like Receptors to inhibit pro-inflammatory cytokines. To learn more about Cytocom, Inc., please visit www.cytocom.comAbout Cleveland BioLabsCleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Cleveland BioLabs’ proprietary platform of Toll-like immune receptor activators addresses conditions such as radiation sickness and cancer treatment side effects. Cleveland Biolabs’ most advanced product candidate, Entolimod is being developed as a medical radiation countermeasure for preventing death from acute radiation syndrome and, through its joint venture with Everon Biosciences, LLC – Genome Protection, Inc. – for other anticancer and antiaging indications. Additionally, Cleveland BioLabs also conducts business in the Russian Federation through a joint venture with Joint Stock Company RUSNANO, Panacela Labs, Inc. Cleveland BioLabs maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, please visit http://www.cbiolabs.comAdditional Information and Where to Find ItCleveland BioLabs plans to file a Registration Statement on Form S-4 containing a proxy statement/prospectus of Cleveland BioLabs and other documents concerning the proposed merger with the SEC. Before making any voting decision, Cleveland BioLabs stockholders are urged to read the proxy statement/prospectus in its entirety when it becomes available and any other documents filed by Cleveland BioLabs with the SEC in connection with the proposed merger or incorporated by reference therein because they will contain important information about the proposed transaction and the parties to the proposed transaction. Investors and stockholders will be able to obtain a free copy of the proxy statement/prospectus (when it becomes available) and other documents containing important information about Cleveland BioLabs and Cytocom, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Cleveland BioLabs also makes available free of charge at www.cbiolabs.com (in the “Investors” section), copies of materials that Cleveland BioLabs files with, or furnishes to, the SEC.Participants in the SolicitationThis document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. Cleveland BioLabs and Cytocom, and each of their respective directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of Cleveland BioLabs in connection with the proposed merger. Security holders may obtain information regarding the names, affiliations and interests of Cleveland BioLabs’ directors and officers in Cleveland BioLabs’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on April 15, 2020, and Amendment No. 1 to its Annual Report on Form 10-K, which was filed with the SEC on April 29, 2020. To the extent the holdings of Cleveland BioLabs’ securities by the directors and executive officers of Cleveland BioLabs have changed from the amounts set forth in Cleveland BioLabs’ amended Annual Report, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed merger will be included in the proxy statement/prospectus relating to the proposed merger when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov and Cleveland BioLabs’ website at www.cbiolabs.com.Forward Looking Statements:This press release contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this press release, including statements regarding the future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals, the impact of any laws or regulations applicable to Cleveland BioLabs or Cytocom, plans and objectives of management for future operations, the expected ownership in the combined company by the former Cytocom securityholders and securityholders of Cleveland BioLabs as of immediately prior to the merger and governance of the combined company are forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements on the current expectations about future events held by management of both companies. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the control of either company. The actual future results of Cleveland BioLabs or Cytocom may differ materially from those discussed here for various reasons. Cleveland BioLabs discusses many of these risks in Item 1A under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2019, as updated by its other filings with the SEC. Factors that may cause such differences include, but are not limited to, the risk that the proposed merger may not be completed in a timely manner or at all, which may adversely affect Cleveland BioLabs’ business and the price of Cleveland BioLabs’ common stock; the failure of either party to satisfy any of the conditions to the consummation of the proposed merger, including the approval of Cleveland BioLabs’ stockholders; uncertainties as to the timing of the consummation of the proposed merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the proposed merger on Cleveland BioLabs’ business relationships, operating results and business generally; risks that the proposed merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the proposed merger; risks related to diverting management’s attention from each company’s ongoing business operations; the outcome of any legal proceedings that may be instituted against Cleveland BioLabs or Cytocom related to the merger agreement or the proposed merger; unexpected costs, charges or expenses resulting from the proposed merger; each company’s need for additional financing to meet its business objectives; the history of operating losses experienced by both companies; the substantial doubt expressed by each company’s independent auditors about its respective ability to continue as a going concern; each company’s ability to successfully develop, obtain regulatory approval for, and commercialize its products in a timely manner; each company’s plans to research, develop and commercialize its product candidates; each company’s ability to attract collaborators with development, regulatory and commercialization expertise; each company’s plans and expectations with respect to future clinical trials and commercial scale-up activities; each company’s reliance on third-party manufacturers of its product candidates; the size and growth potential of the markets for each company’s product candidates, and each company’s ability to serve those markets; the rate and degree of market acceptance of each company’s product candidates; regulatory requirements and developments in the United States, the European Union and foreign countries; the performance of each company’s third-party suppliers and manufacturers; the success of competing therapies that are or may become available; each company’s ability to attract and retain key scientific or management personnel; Cleveland BioLabs’ historic reliance on government funding for a significant portion of its operating costs and expenses; government contracting processes and requirements; the exercise of control over Cleveland BioLabs by its majority stockholder; the geopolitical relationship between the United States and the Russian Federation as well as general business, legal, financial and other conditions within the Russian Federation; each company’s ability to obtain and maintain intellectual property protection for its product candidates; each company’s potential vulnerability to cybersecurity breaches; and other factors discussed in other SEC filings of Cleveland BioLabs, including its Annual Report on Form 10-K for the year ended December 31, 2019.Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. CONTACT: Tiberend Strategic Advisors, Inc. Investors Maureen McEnroe, CFA/Miriam Weber Miller 212-375-2664/212-375-2694 firstname.lastname@example.org email@example.com Media Johanna Bennett 212-375-2686 firstname.lastname@example.org
AM Best has assigned a Financial Strength Rating of A- (Excellent) and a Long-Term Issuer Credit Rating of "a-" to Sutton Specialty Insurance Company and Sutton National Insurance Company. The outlook assigned to these Credit Ratings (ratings) is stable. Sutton Specialty and Sutton National collectively are referred to as Sutton National Group. Both companies are domiciled in Oklahoma City, OK.